These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9481541)

  • 1. Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination.
    Bourget P; Sertin A; Lesne-Hulin A; Fernandez H; Ville Y; Van Peborgh P
    Eur J Obstet Gynecol Reprod Biol; 1998 Jan; 76(1):21-7. PubMed ID: 9481541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.
    Bourget P; Lesne-Hulin A; Le Reveillé R; Le Bever H; Carsin H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):139-45. PubMed ID: 8787895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.
    Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2001 Aug; 48(2):259-67. PubMed ID: 11481298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.
    Nau R; Kinzig-Schippers M; Sörgel F; Schinschke S; Rössing R; Müller C; Kolenda H; Prange HW
    Antimicrob Agents Chemother; 1997 May; 41(5):987-91. PubMed ID: 9145857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary elimination and hepatic disposition of an association of piperacillin and tazobactam: experimental evaluation.
    Brogard JM; Caro-Sampara F; Westphal JF; Blickle JF; Jehl F
    Drugs Exp Clin Res; 1994; 20(6):247-55. PubMed ID: 7758397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis.
    Dalla Costa T; Nolting A; Kovar A; Derendorf H
    J Antimicrob Chemother; 1998 Dec; 42(6):769-78. PubMed ID: 10052901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of biliary excretion of piperacillin-tazobactam in humans.
    Westphal JF; Brogard JM; Caro-Sampara F; Adloff M; Blicklé JF; Monteil H; Jehl F
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1636-40. PubMed ID: 9257733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations.
    Dalla Costa T; Nolting A; Rand K; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):426-33. PubMed ID: 9352391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
    Mattoes HM; Capitano B; Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Chemotherapy; 2002 May; 48(2):59-63. PubMed ID: 12011536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.
    Sörgel F; Kinzig M
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():39-60. PubMed ID: 8383655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.
    Valtonen M; Tiula E; Takkunen O; Backman JT; Neuvonen PJ
    J Antimicrob Chemother; 2001 Dec; 48(6):881-5. PubMed ID: 11733473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH).
    van der Werf TS; Mulder PO; Zijlstra JG; Uges DR; Stegeman CA
    Intensive Care Med; 1997 Aug; 23(8):873-7. PubMed ID: 9310805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis.
    Tomaselli F; Dittrich P; Maier A; Woltsche M; Matzi V; Pinter J; Nuhsbaumer S; Pinter H; Smolle J; Smolle-Jüttner FM
    Br J Clin Pharmacol; 2003 Jun; 55(6):620-4. PubMed ID: 12814459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis.
    Zaidenstein R; Weissgarten J; Dishi V; Koren M; Soback S; Gips M; Averbuch Z; Simantov R; Assulin E; Golik A
    Perit Dial Int; 2000; 20(2):227-31. PubMed ID: 10809248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment.
    Derendorf H; Dalla Costa T
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):482-8. PubMed ID: 8937930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.
    Dowell JA; Korth-Bradley J; Milisci M; Tantillo K; Amorusi P; Tse S
    J Clin Pharmacol; 2001 Sep; 41(9):979-86. PubMed ID: 11549103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin].
    Pédeboscq S; Dubau B; Frappier S; Hernandez V; Veyssières D; Winnock S; Pometan JP
    Pathol Biol (Paris); 2001 Sep; 49(7):540-7. PubMed ID: 11642016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.